REQUEST A DEMO
Total
USD $0.00
Search more companies

Ankapharma Ecza Deposu Ilac A.S. (Turkiye)

Main Activities: Drugs and Druggists' Sundries Merchant Wholesalers
Full name: Ankapharma Ecza Deposu Ilac Sanayi Ve Ticaret Anonim Sirketi Profile Updated: December 12, 2023
Buy our report for this company USD 29.95 Most recent financial data: 2022 Available in: English Download a sample report

Ankapharma Ecza Deposu Ilac A.S. is a company in Turkiye, with a head office in Istanbul. It operates in the Drugs and Druggists' Sundries Merchant Wholesalers sector. It was established on March 03, 2016. Ankapharma Ecza Deposu Ilac A.S. currently employs 41 (2023) people. In 2022, the company reported a net sales revenue increase of 61.81%. During that time, Ankapharma Ecza Deposu Ilac A.S.’s total assets grew by 108.57%. The net profit margin of Ankapharma Ecza Deposu Ilac A.S. increased by 0.43% in 2022.

Headquarters
No:8 Yukari Dudullu Mahallesi Azimli Sokak Umraniye
Istanbul; Marmara; Postal Code: 34775

Contact Details: Purchase the Ankapharma Ecza Deposu Ilac A.S. report to view the information.

Website: http://www.ankapharma.com.tr

Basic Information
Total Employees:
Purchase the Ankapharma Ecza Deposu Ilac A.S. report to view the information.
Outstanding Shares:
Purchase the Ankapharma Ecza Deposu Ilac A.S. report to view the information.
Incorporation Date:
March 03, 2016
Key Executives
Purchase this report to view the information.
Chairman
Company Performance
Financial values in the chart are available after Ankapharma Ecza Deposu Ilac A.S. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency TRY. Absolute financial data is included in the purchased report.
Net sales revenue
61.81%
Total operating revenue
61.81%
Operating profit (EBIT)
68.61%
Net Profit (Loss) for the Period
168.24%
Total assets
108.57%
Total equity
23.64%
Operating Profit Margin (ROS)
0.09%
Net Profit Margin
0.43%
Return on Equity (ROE)
15.16%
Debt to Equity Ratio
91.26%
Quick Ratio
-0.15%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?